IFN-α治疗白塞病葡萄膜炎的新进展

doi:10.3760/cma.j.issn.1674-845X.2016.07.016

摘要
图/表
参考文献(0)
相关文章 (15)

全文: PDF 4139KB HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要白塞病（BD）是一种累及多系统、多器官的慢性、复发性、全身性疾病。由BD引起的葡萄膜炎是我国常见葡萄膜炎中重要的致盲类型，目前尚无根治方法。IFN-α是一种具有多种生物学效应的细胞因子，具有较强的免疫双向调节作用。近年来IFN-α被尝试用于治疗伴有眼部葡萄膜炎的BD患者，临床研究发现IFN-α治疗能够有效控制BD葡萄膜炎病情的发展，降低复发频率，对于反复发作、常规激素和免疫抑制剂治疗无效的BD葡萄膜炎患者，不失为一种较好的治疗选择；但其作用的机制、长期的治疗效果，仍需进一步的临床研究观察。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	蔡莉
	高玮
	王颖维
	王雨生

关键词 ： IFN-α, 白塞病, 葡萄膜炎, 治疗进展

Abstract：Behcet disease (BD) is a chronic, recrudescent, systemic disease which involves multi-organ. Uveitis caused by BD is a common type of uveitis inducing blindness in China. There is no radical cure for this kind of uveitis at present. IFN-α is a kind of cytokine which has multiple biological effects. It has a dual immunomodulatory activity, and has been applied to uveitis patients with BD disease in recent years. Clinical investigation has found IFN-α treatment is effective in controlling the progress of BD uveitis, reducing the frequency of disease recurrence. For the BD uveitis patients who are resistance to normal steroids and immunosuppressive drugs, IFN-α treatment will bring new hope. Otherwise, the mechanism and long-term effect of IFN-α treatment need more clinical studies.

Key words： IFN-α Behcet′s disease Uveitis Progress of treatment

通讯作者: 蔡莉，Email：caili@fmmu.edu.cn

引用本文:

蔡莉,高玮,王颖维, 王雨生. IFN-α治疗白塞病葡萄膜炎的新进展[J]. 中华眼视光学与视觉科学杂志, 2016, 18(7): 446-448. Cai Li*, Gao Wei, Wang Yingwei, Wang Yusheng. Progress in IFN-α treatment of uveitis patients with Behcet′s disease. Chinese Journal of Optometry Ophthalmology and Visual science, 2016, 18(7): 446-448. DOI: 10.3760/cma.j.issn.1674-845X.2016.07.016

链接本文:

https://www.cjoovs.com/CN/10.3760/cma.j.issn.1674-845X.2016.07.016 或 https://www.cjoovs.com/CN/Y2016/V18/I7/446

[1]	Mesquida M, Molins B, Llorenc V, et al. Current and future treatments for Behcet′s uveitis: road to remission[J]. Int Ophthalmol,2014,34(2):365-381. DOI:10.1007/s10792-013-9788-5.
[2]	Khairallah M, Accorinti M, Muccioli C, et al. Epidemiology of Behcet disease[J]. Ocul Immunol Inflamm,2012,20(5):324-335. DOI:10.3109/09273948.2012.723112.
[3]	Yang P, Fang W, Meng Q, et al. Clinical features of chinese patients with Behcet′s disease[J]. Ophthalmology,2008,115(2):312-318.e4. DOI:10.1016/j.ophtha.2007.04.056.
[4]	Davatchi F, Shahram F, Chams-Davatchi C, et al. Behcet′s disease: from East to West[J]. Clin Rheumatol,2010,29(8):823-833. DOI:10.1007/s10067-010-1430-6.
[5]	吴红华,李国华,陈华,等. 白塞病眼病111例临床分析[J]. 中华内科杂志,2014,53(1):44-47. DOI:10.3760/cma.j.issn.0578-1426. 2014.01.011.
[6]	Mendes D, Correia M, Barbedo M, et al. Behcet′s disease—a contemporary review[J]. J Autoimmun,2009,32(3-4):178-188. DOI:10.1016/j.jaut.2009.02.011.
[7]	Kitaichi N, Miyazaki A, Iwata D, et al. Ocular features of Behcet′s disease: an international collaborative study[J]. Br J Ophthalmol,2007,91(12):1579-1582. DOI:10.1136/bjo.2007.123554.
[8]	Theofilopoulos AN, Baccala R, Beutler B, et al. Type I interferons (alpha/beta) in immunity and autoimmunity[J]. Annu Rev Immunol,2005,23:307-336. DOI:10.1146/annurev.immunol.23.021704.115843.
[9]	Markomichelakis N, Delicha E, Masselos S, et al. A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behcet′s disease: a comparative 4-week study[J]. Rheumatology (Oxford),2011,50(3):593-597. DOI:10.1093/rheumatology/keq366.
[10]	Yang DS, Taylor SR, Lightman SL. Interferon-alpha in the management of patients with Behcet′s disease[J]. Br J Hosp Med (Lond),2008,69(10):575-579. DOI:10.12968/hmed.2008.69.10.31317.
[11]	Saadoun D, Bodaghi B, Bienvenu B, et al. Biotherapies in inflammatory ocular disorders: Interferons, immunoglobulins, monoclonal antibodies[J]. Autoimmun Rev,2013,12(7):774-783. DOI:10.1016/j.autrev.2013.02.002.
[12]	Evereklioglu C. Current concepts in the etiology and treatment of Behcet disease[J]. Surv Ophthalmol,2005,50(4):297-350. DOI: 10.1016/j.survophthal.2005.04.009.
[13]	Portales P, Reynes J, Pinet V, et al. Interferon-alpha restores HIV-induced alteration of natural killer cell perforin expression in vivo[J]. AIDS, 2003,17(4):495-504. DOI:10.1097/01.aids.00000 50816.06065.b1.
[14]	Deuter CM, Zierhut M, M?hle A, et al. Long-term remission after cessation of interferon-α treatment in patients with severe uveitis due to Behcet′s disease[J]. Arthritis Rheum,2010,62(9):2796-2805. DOI:10.1002/art.27581.
[15]	Tugal-Tutkun I, Güney-Tefekli E, Urgancioglu M. Results of interferon-alfa therapy in patients with Behcet uveitis[J]. Graefes Arch Clin Exp Ophthalmol,2006,244(12):1692-1695. DOI:10.1007/s00417-006-0346-y.
[16]	Gueudry J, Wechsler B, Terrada C, et al. Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behcet disease[J]. Am J Ophthalmol,2008, 146(6):837-844.e1. DOI:10.1016/j.ajo.2008.08.038.
[17]	Deuter CM, Koetter I, Guenaydin I, et al. Interferon alfa-2a: a new treatment option for long lasting refractory cystoid macular edema in uveitis? A pilot study[J]. Retina,2006,26(7):786-791. DOI:10.1097/01.iae.0000244265.75771.71.
[18]	Hatemi G, Silman A, Bang D, et al. Management of Behcet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behcet disease[J]. Ann Rheum Dis,2009,68(10):1528-1534. DOI:10.1136/ard.2008.087957.
[19]	K?tter I, Günaydin I, Zierhut M, et al. The use of interferon alpha in Behcet disease: review of the literature[J]. Semin Arthritis Rheum,2004,33(5):320-335.
[20]	Liu X, Yang P, Wang C, et al. IFN-alpha blocks IL-17 production by peripheral blood mononuclear cells in Behcet′s disease[J]. Rheumatology (Oxford),2011,50(2):293-298. DOI:10.1093/rheumatology/keq330.
[21]	Plskova J, Greiner K, Muckersie E, et al. Interferon-alpha: a key factor in autoimmune disease?[J]. Invest Ophthalmol Vis Sci,2006,47(9):3946-3950. DOI:10.1167/iovs.06-0058.
[22]	Warde N. Therapy: Behcet uveitis: good results for IFN-alpha-2a[J]. Nat Rev Rheumatol,2010,6(8):437. DOI:10.1038/nrrheum.2010.115.